Status:
UNKNOWN
Ketamine Infusions for Major Depression Disorder
Lead Sponsor:
Sheba Medical Center
Collaborating Sponsors:
Tel Aviv University
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Ketamine has been safely used for induction and maintenance of anesthesia for decades and more recently has been used for chronic pain. Ketamine is a noncompetitive, high-affinity antagonist of the N-...
Detailed Description
Major depressive disorder (MDD) is one of the leading causes of disability worldwide (Collins, Patel et al. 2011). A substantial proportion of patients do not achieve adequate remission despite multip...
Eligibility Criteria
Inclusion
- Diagnosis of Major Depressive disorder, chronic and/or recurrent of at least at moderate severity, determined as reflected by baseline scores of ≥32 on the Inventory of Depressive Symptomatology -Clinician rated IDS-C30
- Patients with demonstrated insufficient response to ≥2 adequate antidepressant trials in the current episode
Exclusion
- Current psychotic or dissociative symptoms
- Severe personality disorder with psychosis or dissociative symptoms
- Lifetime history of psychotic mania
- Substance use disorder
- Current suicidal ideation
- Uncontrolled elevated blood pressure, non-sinus rhythm, unstable ischemic heart disease, uncorrected hyper thyroidism, and for women, pregnancy or the initiation of or female hormonal treatment \<3 months
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2017
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02219867
Start Date
August 1 2014
End Date
August 1 2017
Last Update
August 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba MC
Ramat Gan, Israel, 5265601